Human medicines European public assessment report (EPAR): Saphnelo, anifrolumab, Date of authorisation: 14/02/2022, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Saphnelo, anifrolumab, Date of authorisation: 14/02/2022, Revision: 9, Status: Authorised

Healthcare Professionals' Working Party (HCPWP) plenary meeting February 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, 3 February 2026

Healthcare Professionals' Working Party (HCPWP) plenary meeting February 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, 3 February 2026

Human medicines European public assessment report (EPAR): Pomalidomide Teva, pomalidomide, Date of authorisation: 14/11/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Pomalidomide Teva, pomalidomide, Date of authorisation: 14/11/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Hukyndra, adalimumab, Date of authorisation: 15/11/2021, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Hukyndra, adalimumab, Date of authorisation: 15/11/2021, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Koselugo, selumetinib, Date of authorisation: 17/06/2021, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Koselugo, selumetinib, Date of authorisation: 17/06/2021, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Abevmy, bevacizumab, Date of authorisation: 21/04/2021, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Abevmy, bevacizumab, Date of authorisation: 21/04/2021, Revision: 12, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.